Background: FV-Short is a normal splice variant of Factor V (FV) having a short B do-
with a Q (FV Leiden) is associated with the APC-resistance phenotype, which is the most common inherited thrombophilia described. [4] [5] [6] In its unactivated circulating form, FV has very low affinity for FXa and no procoagulant activity. 7 This is in stark contrast to fully activated
FVa that in the PTase complex binds FXa with very high (sub-nM) affinity. 8 The three cleavage sites in FV have different sensitivity to thrombin and FXa, R709 > R1018 > R1545, and intermediates are generated with partial FXa cofactor activity. 7 Full activation requires the cleavage at R1545, which results in the release of the B domain and exposure of the FXa-binding site. 7, 8 The large B domain comprises two highly charged regions that are shown to be important for keeping FV in a procofactor state. FV-deficiency is a rare autosomal recessive bleeding disease having variable severity and bleeding phenotype. 9 It has been shown that FV-deficiency is associated with low plasma levels of tissue factor pathway inhibitor (TFPIα), which regulates the initiation step of the extrinsic tissue factor (TF) pathway. 10 Immune depletion of FV results in depletion of TFPIα, which demonstrates that TFPIα is circulating in complex with FV. 10, 11 TFPIα, the full-length isoform of TFPI, comprises three Kunitz domains and a highly charged C-terminal extension that contains the binding site for the acidic region in the B-domain of FV. 11, 12 The full length TFPIα (≈0.2 nmol L −1 in plasma) constitutes around 20% of total TFPI in circulation. 13 The major part of TFPI in plasma, which is complexed with lipoproteins, has only two Kunitz domains and an unclear functional significance. 13 The first Kunitz domain of full length
TFPIα inhibits FVIIa, the second inhibits FXa, whereas the third Kunitz domain interacts with protein S. [13] [14] [15] [16] The interaction between TFPIα and protein S is associated with stimulation of the inhibition of FXa by TFPIα. 17, 18 Full length FV has also been reported to potentiate the activity of TFPIα . 19, 20 Recently, it was reported that the TFPIα stimulation of high concentrations of full length FV (30 nmol L −1 ) requires the presence of protein S (100 nM). 
| MATERIALS AND METHODS

| Materials
Human prothrombin, FXa, thrombin, FV monoclonal antibodies AHV5146 and AHV5112, a polyclonal TFPI antibody (PAHTFPI), and FV-deficient plasma were from Hematologic Technologies, Inc (Essex Junction, VT, USA). A rabbit anti-protein S (A0384) from Dako (Glostrup, Denmark) was used. TFPIα expressed in eukaryotic cells was a kind gift from Dr. T. Hamuro at the Chemo-Sero-Therapeutic
Research Institute, Japan. Protein S was purified as previously described. 24 Human FV was purified from plasma as described. 25, 26 Phosphatidylserine (PS), phosphatidyl ethanolamine (PE) and phosphatidyl choline (PC) were from Avanti Polar Lipids. Phospholipid vesicles were prepared using the LiposoFast basic extruder (Armatis, Germany) as previously described. 27 The phospholipid vesicles were used within 2 days. Synthetic substrates S-2238 and S2765 were kindly provided by Chromogenix Ltd., Milan, Italy.
| Recombinant FV-variants
FV-Short was created as previously described. 23 Quikchange site directed mutagenesis (Stratagene, San Diego, CA, USA) was used to replace R709 and R1545 (numbering as in full length FV) with Q and the nucleotide sequence of the whole FV-Short coding region was checked using Sanger sequencing. 28 The FV-Short variant is denoted FV-Short QQ. Stable BHK cell clones expressing the FV-Short variants and full length FV were created and the proteins purified as described. 29, 30 On SDS-PAGE, the purified proteins migrated as 250 kDa bands. After cleavage with thrombin, FV-Short generated the expected heavy (≈115 kDa) and light (≈75 kDa) chains of FVa (not shown). The double mutant FV-Short QQ was resistant to thrombin.
| Electrophoretic techniques
SDS-PAGE was performed using standard techniques. For western blotting, 4-15% gradient SDS-PAGE gels (Bio-Rad, Hercules, CA, USA)
were used.
| Thrombin generation assay
Thrombin generation was performed as previously described with slight variations. 23 Either 40 uL pooled normal citrated (50 ug mL Figure 3C ). Similar results as those in Figure 3C were obtained when protein S was raised to 150 nmol L −1 protein S (not shown).
| Effects on thrombin generation of TFPIα and FV-Short in FV-deficient plasma
Increasing concentrations of FV-Short, or thrombin-cleaved FVShort, were added to FV-deficient plasma and a thrombin generation 
) was monitored for 900 seconds as described in Figure 1 Figure 7C ) Moreover, the intrinsic procoagulant effect of FV-Short was evident when protein S was blocked, with shortening of the lag phase and increased thrombin peak height ( Figure 7C ). 
| Thrombin-resistant FV-Short QQ as synergistic
| DISCUSSION
The recent elucidation of the molecular mechanisms of the East Texas
Bleeding disorder revealed that FV-Short, a splice variant of FV lacking 702 amino acid residues of the activation peptide B domain, is an important carrier of TFPIα in circulation. 23 In this disease, a point ). In C, antiprotein S (anti-ProtS) (100 ug mL to results in decreased TFPIα. 34 However, we could not detect any protein S in the immune precipitate of TFPIα from normal plasma, whereas FV-Short and intact FV were readily observed. 23 This may suggest that the protein S-TFPIα interaction is of lower affinity, which is also compatible with the high molar concentration of protein S in plasma, ≈100 nmol L −1 free protein S and ≈200 nmol L −1 in complex with C4b-binding protein. ). D, the importance of protein S was investigated by adding anti-protein S (antiProtS) (100 ug mL 
